Critical Reminder for Mereo BioPharma Shareholders: Act Before April 6, 2026

Important Alert for Mereo BioPharma Investors

Faruqi & Faruqi, LLP, a prominent national law firm specializing in securities litigation, has issued a crucial reminder for investors involved with Mereo BioPharma Group plc. If you acquired Mereo securities between June 5, 2023, and December 26, 2025, it’s essential to consider the forthcoming deadline for a federal securities class action on April 6, 2026.

The law firm is actively investigating claims against Mereo BioPharma as part of this legal action, which alleges that the company, along with its executives, breached federal securities laws by providing misleading statements regarding two significant clinical trials—the ORBIT and COSMIC programs. These investigations stem from serious concerns that the outcomes of these studies did not meet the primary endpoints for reducing the clinical fracture rate, a critical measure for patients and stakeholders alike.

On December 29, 2025, Mereo's stock faced a sharp decline when the company announced that both Phase 3 studies failed to achieve their primary objectives. Following this announcement, Mereo’s stock price plummeted by 87.64%, closing at a mere $0.28 per share, a dramatic decline that has understandably left many investors worried.

James (Josh) Wilson, a partner at Faruqi & Faruqi, emphasizes the importance of acting promptly. He urges affected investors to reach out for a discussion about their legal options. Engaging with the firm not only offers an avenue for recouping potential losses but may also provide vital updates on the lawsuit’s progression.

Eligible investors can choose to ally with the court-appointed lead plaintiff, who will play an integral role in overseeing the litigation process. This position will be filled by the investor most significantly impacted, facilitating their participation in class proceedings. While one can opt to become a lead plaintiff, any member of the class could also choose to stay uninvolved and still retain rights to recover any potential damages awarded to the class as a whole.

Faruqi & Faruqi encourages anyone who may possess pertinent information regarding Mereo BioPharma’s operations to come forward. Whistleblowers and ex-employees are urged to join the conversation, as their insights could be pivotal in strengthening this class action suit.

To take proactive steps toward your financial security and stay informed about the legal proceedings against Mereo BioPharma, additional information is readily available through Faruqi & Faruqi's website or by contacting Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

In a volatile market like today’s, informing oneself about potential recovery avenues is essential to protecting your investment. Investors should not underestimate the significance of this class action filed against Mereo, especially given the stark financial implications that have arisen from the clinical trial results—an aspect that investors did not foresee based on previous representations made by the company.

Stay connected with updates from Faruqi & Faruqi on platforms like LinkedIn and X. This situation underscores the importance of vigilance in the capital markets, particularly in the context of biotechnology investments that can rapidly change due to trial outcomes, market perceptions, and regulatory compliance.

Conclusion

Investors should act without delay as the April deadline approaches. By collaborating with legal counsel, individuals can safeguard their rights and explore potential claims linked to notable corporate misrepresentation. Taking informed action may ultimately assist in mitigating the adverse financial fallout from this unfolding scenario involving Mereo BioPharma.